Independent of ErbB1 gene copy number, EGF stimulates migration but is not associated with cell proliferation in non-small cell lung cancer

Cancer Cell International

Gláucia Maria Machado-Santelli¹  Beatriz Araújo Cortez¹  Paula Rezende-Teixeira¹  Camila Lauand¹ 

[1] Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 1524, Butantã, São Paulo, SP 05508-000, Brazil

关键词: Cell migration;    Tyrosine kinase inhibitor;    Proliferation;    Epidermal growth factor;    Lung cancer;    Epidermal growth factor receptor;   

Others  :  793970
DOI  :  10.1186/1475-2867-13-38

 received in 2012-12-13, accepted in 2013-04-23,  发布年份 2013

【 摘 要 】

Background

Lung cancer often exhibits molecular changes, such as the overexpression of the ErbB1 gene. ErbB1 encodes epidermal growth factor receptor (EGFR), a tyrosine kinase receptor, involved mainly in cell proliferation and survival. EGFR overexpression has been associated with more aggressive disease, poor prognosis, low survival rate and low response to therapy. ErbB1 amplification and mutation are associated with tumor development and are implicated in ineffective treatment. The aim of the present study was to investigate whether the ErbB1 copy number affects EGFR expression, cell proliferation or cell migration by comparing two different cell lines.

Methods

The copies of ErbB1 gene was evaluated by FISH. Immunofluorescence and Western blotting were performed to determine location and expression of proteins mentioned in the present study. Proliferation was studied by flow cytometry and cell migration by wound healing assay and time lapse.

Results

We investigated the activation and function of EGFR in the A549 and HK2 lung cancer cell lines, which contain 3 and 6 copies of ErbB1, respectively. The expression of EGFR was lower in the HK2 cell line. EGFR was activated after stimulation with EGF in both cell lines, but this activation did not promote differences in cellular proliferation when compared to control cells. Inhibiting EGFR with AG1478 did not modify cellular proliferation, confirming previous data. However, we observed morphological alterations, changes in microfilament organization and increased cell migration upon EGF stimulation. However, these effects did not seem to be consequence of an epithelial-mesenchymal transition.

Conclusion

EGFR expression did not appear to be associated to the ErbB1 gene copy number, and neither of these aspects appeared to affect cell proliferation. However, EGFR activation by EGF resulted in cell migration stimulation in both cell lines.

【 授权许可】

   
2013 Lauand et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Jemal A, Thun MJ, Howe HL, Weir HK, Center MM, Ward E, Wu X-C, Eheman C, Anderson R, Kohler B, Edwards BK, Ries L a G: Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100:1672-1694.
• [2]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer Statistics , 2009 BOTH SEXES FEMALE BOTH SEXES ESTIMATED DEATHS. CA Cancer J Clin 2009, 59:225-249.
• [3]Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
• [4]Maxwell DP: REVIEWS. Lancet Oncol 2001, 2:533-543.
• [5]Yang L, Parkin DM, Ferlay J, Li L, Chen Y: Estimates of Cancer Incidence in China for 2000 and Projections for 2005 Estimates of Cancer Incidence in China for 2000 and Projections for 2005. Cancer Epidemiol Biomarkers Prev 2005, 14(1):243-250.
• [6]Sharma SV, Settleman J: ErbBs in lung cancer. Exp Cell Res 2009, 315:557-571.
• [7]Wang Y, Minoshima S, Shimizu N: Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved fish technique. The Japanese Journal Of Human Genetics 1993, 38:399-406.
• [8]Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003, 284:31-53.
• [9]Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J: Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 2009, 35:354-363.
• [10]Sorkin A, Von Zastrow M: Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 2002, 3:600-614.
• [11]Lewis TS, Shapiro PSAN: Signal transduction through MAP kinase cascades. Adv Cancer Res 1998, 74:49-139.
• [12]Osaki LH, Figueiredo PM, Alvares EP, Gama P: EGFR is involved in control of gastric cell proliferation through activation of MAPK and Src signalling pathways in early-weaned rats. Cell Prolif 2011, 44:174-182.
• [13]Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
• [14]Lurje G, Lenz H-J: EGFR signaling and drug discovery. Oncology 2009, 77:400-410.
• [15]Jaramillo ML, Banville M, Collins C, Paul-Roc B, Bourget L, O’Connor-McCourt M: Differential sensitivity of A549 non-small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors. Cancer Biol Ther 2008, 7:557-568.
• [16]Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Ho AH, Danenberg PV: Advances in Brief Epidermal Growth Factor Receptor and HER2-neu mRNA Expression in Non-Small Cell Lung Cancer Is Correlated with. Survival 2001, 7:1850-1855.
• [17]Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP: Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005, 65:226-235.
• [18]Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T, Takada M, Fukuoka M, Nakagawa K: Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 2007, 67:2046-2053.
• [19]Mitsudomi T: Advances in target therapy for lung cancer. Jpn J Clin Oncol 2010, 40:101-106.
• [20]Heigener DF, Reck M: Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib. Adv Ther 2011, 28:126-133.
• [21]Pao W, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H, Miller V a, Politi K a: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
• [22]Miller V a: EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. Semin Oncol Nurs 2008, 24:27-33.
• [23]Zhu J, Zhong W, Zhang G, Li R, Zhang X, Guo A, Zhang Y, An S, Mok TS, Wu Y: Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Lett 2008, 265:307-317.
• [24]Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW, Lam WL, Varella-Garcia M, Minna JD, Gazdar AF: Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009, 4:e4576.
• [25]Bonaldo MF, Pestano MC, Ribeiro MC, Machado-Santelli GM, Mori LOA: Comparative characterization of a human large cell lung carcinoma cell line and the xenograft derived cell line. Cell Biol Int Rep 1991, 15:229-241.
• [26]Bustin S a: Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002, 29:23-39.
• [27]Bustin S a: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000, 25:169-193.
• [28]Zeisel A, Yitzhaky A, Koerner C, Lauriola M, Cohen-Dvashi H, Köstler WJ, Yarden Y, Wiemann S, Domany E: CMA: A Desktop Application for Quantitative Collective Cell Migration Analysis. J Biomol Screen 2012, 5-10.
• [29]Agelopoulos K, Greve B, Schmidt H, Pospisil H, Kurtz S, Bartkowiak K, Andreas A, Wieczorek M, Korsching E, Buerger H, Brandt B: Selective regain of egfr gene copies in model MDA-MB-468. BMC Cancer 2010, 10:e78. BioMed Central Full Text
• [30]Tidow N, Boecker A, Schmidt H, Agelopoulos K, Boecker W, Buerger H: Distinct Amplification of an Untranslated Regulatory Sequence in the egfr Gene Contributes to Early Steps in Breast Cancer Development Advances in Brief Distinct Amplification of an Untranslated Regulatory Sequence in the egfr Gene Contributes to Early St. Cancer Res 2003, 63(6):1172-1178.
• [31]Cortez BDA, Quassollo G, Caceres A, Machado-Santelli GM: The fate of chrysotile-induced multipolar mitosis and aneuploid population in cultured lung cancer cells. PLoS One 2011, 6:e18600.
• [32]Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Crowley J, Gandara DR, Bunn P a, Franklin W a: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2005, 23:6838-6845.
• [33]Varella-Garcia M: Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 2006, 1:19. BioMed Central Full Text
• [34]Sekido Y, Fong KM, Minna JD: Molecular genetics of lung cancer. Annu Rev Med 2003, 54:73-87.
• [35]Giaccone G, Johnson BE, Eberhard D a: Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008, 26:983-994.
• [36]Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F: Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers. Molecular cancer research: MCR 2007, 5:393-401.
• [37]Stoscheck CM, Carpenter G: Down Regulation of Epidermal Growth Factor Receptors: Fibroblasts Direct Demonstration of Receptor Degradation in Human. J Cell Biol 1984, 98(3):1058-1053.
• [38]Beguinot L, Lyall RM, Willingham MC, Pastan I: Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes. Proc Natl Acad Sci USA 1984, 81:2384-2388.
• [39]Hofman EG, Bader AN, Voortman J, Van den Heuvel DJ, Sigismund S, Verkleij AJ, Gerritsen HC, Henegouwen PMP VBe: Ligand-induced EGF receptor oligomerization is kinase-dependent and enhances internalization. J Biol Chem 2010, 285:39481-39489.
• [40]Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y: Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci USA 2005, 102:1915-1920.
• [41]Oliveira S, Schiffelers RM, Van der Veeken J, Van der Meel R, Vongpromek R, Van Bergen En Henegouwen PMP, Storm G, Roovers RC: Downregulation of EGFR by a novel multivalent nanobody-liposome platform. Journal of controlled release: official journal of the Controlled Release Society 2010, 145:165-175.
• [42]Nishimura Y, Bereczky B, Ono M: The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines. Histochem Cell Biol 2007, 127:541-553.
• [43]Bost F, McKay R, Dean N, Mercola D: The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells. J Biol Chem 1997, 272:33422-33429.
• [44]Hou M-F, Kuo H-C, Li J-H, Wang Y-S, Chang C-C, Chen K-C, Chen W-C, Chiu C-C, Yang S, Chang W-C: Orai1/CRACM1 overexpression suppresses cell proliferation via attenuation of the store-operated calcium influx-mediated signalling pathway in A549 lung cancer cells. Biochim Biophys Acta 1810, 2011:1278-1284.
• [45]Puri N, Salgia R: Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. Journal of carcinogenesis 2008, 7:e9.
• [46]Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho R a: Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (New York, N.Y.) 2007, 318:287-290.
• [47]Guo A, Villén J, Kornhauser J, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, Wang Y, MacNeill J, Mitchell J, Gygi SP, Rush J, Polakiewicz RD, Comb MJ, Lee K a: Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008, 105:692-697.
• [48]Denlinger CE, Ikonomidis JS, Reed CE, Spinale FG: Epithelial to mesenchymal transition: the doorway to metastasis in human lung cancers. J Thorac Cardiovasc Surg 2010, 140:505-513.
• [49]Peter Y, Comellas A, Levantini E, Ingenito EP: Steven D:Epidermal growth factor receptor and claudin-2 participate in A549 permeability and remodeling: implicationsfor non-small cell lung cancer tumor colonization. Mol. Carcinog. 2009, 48:488-497.
• [50]Manelli-Oliveira R, Machado-Santelli GM: Cytoskeletal and nuclear alterations in human lung tumor cells: a confocal microscope study. Histochem Cell Biol 2001, 115(5):403-411.
• [51]Holz C, Niehr F, Boyko M, Hristozova T, Distel L, Budach V, Tinhofer I: Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells. Radiother Oncol 2011, 101:158-164.